Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 21,444 | 2,860 | 2,196 | 11,510 | 935 |
| Cost of Goods | 2,144 | 1,083 | 1,147 | 709 | 679 |
| Gross Profit | 19,300 | 1,777 | 1,049 | 10,801 | 256 |
| Operating Expenses | 24,840 | 24,918 | 26,364 | 31,688 | 14,199 |
| Operating Income | -5,396 | -23,058 | -25,168 | -20,178 | -13,264 |
| Interest Expense | 985 | 1,286 | 735 | 494 | 521 |
| Other Income | -515 | 4,568 | -120 | -1,202 | 9 |
| Pre-tax Income | -6,896 | -19,776 | -26,023 | -21,874 | -13,776 |
| Income Tax | -75 | -100 | 324 | 94 | -4 |
| Net Income Continuous | -6,821 | -19,676 | -26,347 | -21,968 | -13,772 |
| Net Income Discontinuous | N/A | -46 | 8,488 | 4,241 | 4,160 |
| Net Income | $-6,821 | $-19,722 | $-17,859 | $-17,727 | $-9,612 |
| EPS Basic Total Ops | -0.08 | -0.24 | -0.28 | -0.28 | -0.15 |
| EPS Basic Continuous Ops | -0.08 | -0.24 | -0.42 | -0.35 | -0.22 |
| EPS Basic Discontinuous Ops | N/A | 0.00 | 0.13 | 0.07 | 0.07 |
| EPS Diluted Total Ops | -0.08 | -0.24 | -0.28 | -0.28 | -0.15 |
| EPS Diluted Continuous Ops | -0.08 | -0.24 | -0.42 | -0.35 | -0.22 |
| EPS Diluted Discontinuous Ops | N/A | 0.00 | 0.13 | 0.07 | 0.07 |
| EPS Diluted Before Non-Recurring Items | -0.13 | -0.26 | -0.42 | N/A | N/A |
| EBITDA(a) | $-4,340 | $-21,345 | $-25,014 | $-8,647 | $-9,001 |